You very well might be right. The fact is Howard suggests that guys who got frozen Provenge could have done worse than guys who did not get that. Fact #1 is he knows that is not true because he's seen that data presented.
Fact #2 is that you could have 10,000 patients in this trial and the problem you suggest (guys who don't rollover could do so for some other reason, probably related to health which makes them less likely to survive longer anyway) and you still wouldn't know.
Fact #3 is this is not a problem peculiar to the Provenge trial. The fact the guys who did no rollover did worse than guys who did is probably true in almost any rollover trial where the study agent is truly active.
Fact #4 is the control arm of the Provenge trial (21.4 months) was comparable to the asymptomatic data from the Tax-327 trial (q3w 23, Q1w 21.1, Mito 19.8) and comparable to that predicted by the Halabi nomogram (20.1 if memory serves). All this data Howard has seen because he was sitting feet away from me when it was presented.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC
